Soriot sharpens broom in AstraZeneca C-suite sweep
This article was originally published in Scrip
AstraZeneca's new CEO Pascal Soriot has wasted little time in putting his stamp on the troubled company, eliminating R&D chief Martin Mackay and global commercial head Tony Zook in a management shake up.
You may also be interested in...
Ten years at AstraZeneca PLC have prepared US President and Executive Vice President of North America Paul Hudson for his next C-suite job, but unfortunately for his current employer that gig is with a major competitor – Novartis AG.
The third quarter could bring US approvals for a range of novel drugs, including the first treatment for a common eye disease, the first US approval of PD-1/L1 inhibitor from a Chinese firm, and the first oral therapy for postpartum depression.
Impressive overall survival data from the Phase III ADAURA trial should boost both EGFR testing in non-small cell lung cancer, and sales of the blockbuster NSCLC therapy.